文献速递炎症性肠病

儿童克罗恩病一线英夫利昔单抗与常规治疗的5年随访随机试验

Randomized Trial Comparing 5-Year Follow-Up of First-Line Infliximab to Conventional Therapy in Pediatric Crohn's Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2026-07-04

BACKGROUND & AIMS: The TISKids study previously demonstrated that first-line infliximab was more effective than conventional treatment in achieving clinical remission without treatment escalation at 52 weeks in children with moderate-to-severe Crohn's disease.…

要点

  • 5年时几乎所有患者均需额外克罗恩病相关治疗,两组无显著差异
  • 一线英夫利昔单抗延迟了重启生物制剂的需求(65周 vs 31周)
  • 中重度儿童克罗恩病诊断时宜早期并维持英夫利昔单抗治疗

核心结论

  • 5年随访显示,无论一线英夫利昔单抗或常规治疗,几乎所有中重度儿童克罗恩病患者均需额外治疗。
  • 一线英夫利昔单抗可延迟启动生物制剂的时间,提示其可作为诊断时的优选治疗。

研究设计与样本

  • 患者随机接受一线英夫利昔单抗(5次输注后停用)或常规治疗(全肠内营养或泼尼松龙),两组均接受硫唑嘌呤维持。

临床怎么用

  • 对于新诊断中重度儿童克罗恩病,一线英夫利昔单抗可延迟后续生物制剂需求,可考虑作为初始治疗选择。
  • 需向患者及家属强调中重度克罗恩病需早期并维持英夫利昔单抗治疗,即使初始诱导后停药仍可能需重启治疗。

局限性

  • 开放标签设计可能影响部分结局评估。
  • 一线英夫利昔单抗组仅5次输注后停用,未评估持续维持治疗的长期效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The TISKids study previously demonstrated that first-line infliximab was more effective than conventional treatment in achieving clinical remission without treatment escalation at 52 weeks in children with moderate-to-severe Crohn's disease. We investigated 5-year outcomes. METHODS: The TISKids study is a multicenter, open-label, randomized controlled trial in newly diagnosed, untreated patients with Crohn's disease aged 3 to 17 years (weighted Pediatric Crohn's Disease Activity Index >40). Patients were randomized to first-line infliximab (5 infliximab infusions, then stopped) or conventional treatment (exclusive enteral nutrition or prednisolone). Both groups received azathioprine maintenance. The primary outcome was sustained clinical remission (weighted Pediatric Crohn's Disease Activity Index <12.5, Crohn's Disease Activity Index <150, or Physician Global Assessment remission) without additional Crohn's disease-related therapy at 5 years. Secondary outcomes included time to (re)start infliximab or another biological treatment. RESULTS: One hundred patients were randomized; 6 were lost to follow-up. At 5 years, sustained clinical remission without additional Crohn's disease-related therapy was observed in 3 of 48 (6%) first-line infliximab patients vs 1 of 46 (2%) conventionally treated patients (P = .617), whereas 42 of 48 (88%) in first-line infliximab and 44 of 46 conventionally treated patients required additional Crohn's disease-related treatment (P = .271). The median time to the (re)start of biologic therapy was 65 weeks (95% confidence interval, 53-122 weeks) for first-line infliximab vs 31 weeks (95% confidence interval, 22-57 weeks) for conventional treatment (P = .037). CONCLUSIONS: After 5 years of follow-up in the TISKids trial, we found that almost all patients required additional Crohn's disease-related treatment, irrespective of induction therapy with 5 infusions of first-line infliximab or conventional treatment. First-line infliximab delayed the need for additional biological treatment, indicating its potential as preferred treatment option for patients with moderate-to-severe Crohn's disease at diagnosis. These findings underscore that patients with moderate-to-severe Crohn's disease require early and maintained treatment with infliximab. This trial is registered in the European Clinical Trials Register (EudraCT 2014-005702-37) and on https://clinicaltrials.gov/study/NCT02517684, Number: NCT02517684.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Vuijk SA, Jongsma MME, Cozijnsen MA, et al. Randomized Trial Comparing 5-Year Follow-Up of First-Line Infliximab to Conventional Therapy in Pediatric Crohn's Disease. Clin Gastroenterol Hepatol. 2026. PMID: 42401249. doi:10.1016/j.cgh.2026.06.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。